{
    "clinical_study": {
        "@rank": "136437", 
        "brief_summary": {
            "textblock": "RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing\n      so they stop growing or die.\n\n      PURPOSE: Phase II trial to study the effectiveness of bortezomib in treating patients who\n      have chronic myelogenous leukemia in chronic or accelerated phase."
        }, 
        "brief_title": "Bortezomib in Treating Patients With Chronic Myelogenous Leukemia", 
        "completion_date": {
            "#text": "March 2005", 
            "@type": "Actual"
        }, 
        "condition": "Leukemia", 
        "condition_browse": {
            "mesh_term": [
                "Leukemia", 
                "Leukemia, Myeloid", 
                "Leukemia, Myelogenous, Chronic, BCR-ABL Positive"
            ]
        }, 
        "detailed_description": {
            "textblock": "OBJECTIVES:\n\n        -  Determine the efficacy of bortezomib, in terms of response rate, duration of response,\n           and survival of patients with Philadelphia chromosome-positive chronic myelogenous\n           leukemia in chronic or accelerated phase.\n\n        -  Assess the toxicity of this drug in these patients.\n\n      OUTLINE: Patients receive bortezomib intravenous (IV) over 3-5 seconds twice weekly on weeks\n      1-2. Treatment repeats every 3 weeks for up to 12 courses in the absence of disease\n      progression or unacceptable toxicity.\n\n      PROJECTED ACCRUAL: A total of 5-30 patients will be accrued for this study within 15-30\n      months."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "DISEASE CHARACTERISTICS:\n\n          -  Diagnosis of Philadelphia (Ph) chromosome-positive chronic myelogenous leukemia (CML)\n             in chronic or accelerated phase, defined as having any of the following:\n\n               -  Peripheral blood (PB) or bone marrow (BM) blasts at least 10% but less than 30%\n\n               -  PB or BM blasts and promyelocytes at least 20%\n\n               -  PB or BM basophils at least 20%\n\n               -  Progressive splenomegaly (at least 10 cm confirmed twice at least 4 weeks apart\n                  or 50% increase in splenomegaly over 4 weeks)\n\n               -  Clonal evolution defined as the presence of additional cytogenetic abnormalities\n                  other than the Ph chromosome\n\n               -  Thrombocytopenia (platelet count less than 100,000/mm^3) unrelated to therapy\n\n               -  Hemoglobin less than 7 g/dL unrelated to therapy or bleeding\n\n          -  Failed prior treatment with imatinib mesylate or intolerant, unable, or unwilling to\n             receive it\n\n          -  Ineligible for higher-priority or higher-efficacy regimens or protocols\n\n          -  No blastic phase CML\n\n        PATIENT CHARACTERISTICS:\n\n        Age:\n\n          -  18 and over\n\n        Performance status:\n\n          -  Eastern Cooperative Oncology Group (ECOG) 0-2\n\n        Life expectancy:\n\n          -  At least 18 weeks\n\n        Hematopoietic:\n\n          -  See Disease Characteristics\n\n        Hepatic:\n\n          -  Bilirubin no greater than 1.5 mg/dL\n\n        Renal:\n\n          -  Creatinine no greater than 1.5 mg/dL OR\n\n          -  Creatinine clearance greater than 60 mL/min\n\n        Other:\n\n          -  No other concurrent illness that would preclude study entry\n\n          -  Not pregnant or nursing\n\n          -  Negative pregnancy test\n\n          -  Fertile patients must use effective contraception\n\n        PRIOR CONCURRENT THERAPY:\n\n        Biologic therapy:\n\n          -  Not specified\n\n        Chemotherapy:\n\n          -  No more than 2 prior cytotoxic regimens in addition to imatinib mesylate and/or\n             hydroxyurea\n\n          -  At least 4 weeks since prior chemotherapy and recovered\n\n          -  Concurrent hydroxyurea and/or anagrelide allowed during first 2 courses\n\n        Endocrine therapy:\n\n          -  Not specified\n\n        Radiotherapy:\n\n          -  At least 4 weeks since prior radiotherapy and recovered\n\n        Surgery:\n\n          -  Not specified\n\n        Other:\n\n          -  See Disease Characteristics\n\n          -  See Chemotherapy\n\n          -  At least 24 hours since prior imatinib mesylate\n\n          -  No other concurrent investigational agents"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "7", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "September 13, 2001", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT00023881", 
            "org_study_id": "CDR0000068872", 
            "secondary_id": [
                "MDA-DM-00274", 
                "NCI-1756", 
                "DM00-274"
            ]
        }, 
        "intervention": {
            "intervention_name": "bortezomib", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": "Bortezomib"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "relapsing chronic myelogenous leukemia", 
            "chronic phase chronic myelogenous leukemia", 
            "accelerated phase chronic myelogenous leukemia", 
            "chronic myelogenous leukemia, BCR-ABL1 positive"
        ], 
        "lastchanged_date": "October 5, 2012", 
        "link": {
            "description": "Clinical trial summary from the National Cancer Institute's PDQ\u00ae database", 
            "url": "http://cancer.gov/clinicaltrials/MDA-DM-00274"
        }, 
        "location": {
            "facility": {
                "address": {
                    "city": "Houston", 
                    "country": "United States", 
                    "state": "Texas", 
                    "zip": "77030-4009"
                }, 
                "name": "MD Anderson Cancer Center at University of Texas"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "Phase II Study of a Proteasome Inhibitor, PS-341 (NSC 681239) in Chronic Myelogenous Leukemia (CML) in Chronic or Accelerated Phase", 
        "overall_official": {
            "affiliation": "M.D. Anderson Cancer Center", 
            "last_name": "Jorge Cortes, MD", 
            "role": "Study Chair"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Institutional Review Board", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "March 2005", 
            "@type": "Actual"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00023881"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "M.D. Anderson Cancer Center", 
        "sponsors": {
            "collaborator": {
                "agency": "National Cancer Institute (NCI)", 
                "agency_class": "NIH"
            }, 
            "lead_sponsor": {
                "agency": "M.D. Anderson Cancer Center", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "July 2001", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "October 2012"
    }, 
    "geocoordinates": {
        "MD Anderson Cancer Center at University of Texas": "29.76 -95.369"
    }
}